Onco Wiki / Bandeira vermelha

Baseline organ dysfunction precluding standard gemcitabine + cisplatin + durvalumab in ad...

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDRF-CHOLANGIOCARCINOMA-ORGAN-DYSFUNCTION
TipoSinal de alerta
Estadoreviewed 2026-04-27 | pending_clinical_signoff
DoençasDIS-CHOLANGIOCARCINOMA
FontesSRC-ESMO-BTC-2023 SRC-NCCN-HEPATOBILIARY

Origem da bandeira vermelha

DefiniçãoBaseline organ dysfunction precluding standard gemcitabine + cisplatin + durvalumab in advanced biliary tract cancer: Child-Pugh B/C cirrhosis or bilirubin >3× ULN (impaired hepatic clearance of gem-cis + FGFR2/IDH1 inhibitors, increased toxicity), CrCl <30 mL/min (cisplatin contraindicated; reduced gemcitabine), or LVEF <50% (FGFR2-inhibitor cardiac monitoring requirement).
Direcção clínicade escalonamento
Categoriadisfunção de órgãos

Lógica de Desencadeamento

{
  "any_of": [
    {
      "finding": "child_pugh_class",
      "value": "B"
    },
    {
      "finding": "child_pugh_class",
      "value": "C"
    },
    {
      "comparator": ">=",
      "finding": "bilirubin_ratio_to_uln",
      "threshold": 3
    },
    {
      "comparator": "<",
      "finding": "creatinine_clearance_ml_min",
      "threshold": 30
    },
    {
      "comparator": "<",
      "finding": "lvef_percent",
      "threshold": 50
    }
  ],
  "type": "lab_value"
}

Notas

Child-Pugh B/C: cisplatin component should be omitted or replaced; consider gemcitabine monotherapy or capecitabine. FGFR2-inhibitors (pemigatinib, futibatinib, infigratinib) require dose adjustment in hepatic impairment per FDA labels. Ivosidenib (IDH1) requires QTc monitoring + dose reduction with hepatic dysfunction. CrCl <30: cisplatin contraindicated — substitute carboplatin or omit. ABC-02 / TOPAZ-1 / KEYNOTE-966 enrolled mostly preserved hepatic function; extrapolation to Child-Pugh B requires individualized risk-benefit.

Usado por

Indicação